Dukoral

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

rekombinantne kolera toksin B podenote, vibrio cholerae 01

Available from:

Valneva Sweden AB

ATC code:

J07AE01

INN (International Name):

cholera vaccine (inactivated, oral)

Therapeutic group:

Cepiva

Therapeutic area:

Cholera; Immunization

Therapeutic indications:

Zdravilo Dukoral je indicirano za aktivno imunizacijo proti bolezni, ki jo povzroča serotip skupine Vibrio cholerae O1 pri odraslih in otrocih, starih od 2 let, ki bodo obiskali endemične / epidemične površine. Uporaba Dukoral je treba določiti na podlagi uradnih priporočil, ob upoštevanju variabilnosti epidemiologija in tveganje stranke bolezni v različnih geografskih področjih in potujejo pogoji. Dukoral ne sme nadomestiti standardne zaščitne ukrepe. V primeru driske ukrepov za rehidracijo, je treba začeti.

Product summary:

Revision: 14

Authorization status:

Pooblaščeni

Authorization date:

2004-04-28

Patient Information leaflet

                                15
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP: MM/LLLL
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v hladilniku.
Ne zamrzujte.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Valneva Sweden AB
105 21 Stockholm, Švedska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/03/263/001 1 odmerek
EU/1/03/263/002 2 x 1 odmerek
EU/1/03/263/003 20 x 1 odmerek
13.
ŠTEVILKA SERIJE
Serija
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
DUKORAL
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
16
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
17
PODATKI NA PRIMARNI OVOJNINI
DUKORAL – PAKIRANJE 20 X 1 ODMEREK (STIČNA OVOJNINA ZA 20 VIAL S
CEPIVOM)
1.
IME ZDRAVILA
DUKORAL supenzija
cepivo proti koleri (inaktivirano, peroralno)
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Učinkovine: 1 odmerek vsebuje
−
31,25 x 10
9
bakterij* vsake od naslednjih sevov bakterije
_V. cholerae_
O1: klasični biotip Inaba
(inaktiviran s toploto), biotip Inaba El Tor (inaktiviran s
formalinom), klasični biotip Ogawa
(inaktiviran s toploto), klasični biotip Ogawa (inaktiviran s
formalinom)
−
1 mg rekombinantne podenote toksina kolera B (rCTB)
*količina bakterij pred inaktivacijo
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje natrij. Za dodatne informacije glejte navodila za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
3 ml suspenzije v viali.
20 x 1 odmerek
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Za peroralno uporabo.
Pred pitjem suspenzijo zmešajte s pufrsko raztopino.
Pred uporabo preberite priloženo navodilo!
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP: MM/LLLL
18
9.
POSEBNA NAVODILA
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Dukoral suspenzija in šumeči prašek za peroralno suspenzijo
cepivo proti koleri (inaktivirano, peroralno)
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsak odmerek suspenzije za cepljenje (3 ml) vsebuje:
−
skupaj 1,25 x 10
11
bakterij naslednjih sevov:
_Vibrio cholerae_
O1 Inaba, klasični biotip (inaktiviran s toploto)
31,25 x 10
9
bakterij*
_Vibrio cholerae_
O1 Inaba, biotip El Tor (inaktiviran s formalinom)
31,25 x 10
9
bakterij*
_Vibrio cholerae_
O1 Ogawa, klasični biotip (inaktiviran s toploto)
31,25 x 10
9
bakterij*
_Vibrio cholerae_
O1 Ogawa, klasični biotip (inaktiviran s
formalinom)
31,25 x 10
9
bakterij*
−
rekombinantno podenoto toksina kolera B (rCTB)
1 mg
(pridobljen s pomočjo bakterije
_V. cholerae_
O1 Inaba, klasičnem biotipu, sev 213)
* Število bakterij pred inaktivacijo.
Pomožne snovi z znanim učinkom:
Natrijev dihidrogenfosfat dihidrat 2,0 mg, dinatrijev hidrogenfosfat
dihidrat 9,4 mg, natrijev klorid
26 mg, natrijev hidrogenkarbonat 3.600 mg, brezvodni natrijev karbonat
400 mg, natrijev saharinat
30 mg, natrijev citrat 6 mg.
En odmerek vsebuje približno 1,1 g natrija.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
suspenzija in šumeči prašek za peroralno suspenzijo:
-
suspenzija za peroralno suspenzijo
-
prašek za peroralno suspenzijo v vrečici
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Cepivo Dukoral je indicirano za aktivno imunizacijo proti bolezni, ki
jo povzroča
_Vibrio cholerae_
serološke skupine O1 pri odraslih in otrocih od dveh let starosti
dalje, ki bodo obiskali epidemična ali
endemična območja.
Uporabo cepiva Dukoral morate določiti na osnovi uradnih priporočil
in pri tem upoštevati
epidemiološko variabilnost ter tveganje za okužbo v različnih
geografskih območjih in pri različnih
potovalnih pogojih.
Cepivo Dukoral ne sme nadomestiti standardnih zaščitnih ukrepov. V
primeru driske morate uporabiti
ukrepe za rehidracijo.
3
4.2
ODMERJANJE IN NAČIN UPORABE
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 06-04-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 06-04-2022
Public Assessment Report Public Assessment Report Bulgarian 06-04-2022
Patient Information leaflet Patient Information leaflet Spanish 06-04-2022
Public Assessment Report Public Assessment Report Spanish 06-04-2022
Patient Information leaflet Patient Information leaflet Czech 06-04-2022
Public Assessment Report Public Assessment Report Czech 06-04-2022
Patient Information leaflet Patient Information leaflet Danish 06-04-2022
Public Assessment Report Public Assessment Report Danish 06-04-2022
Patient Information leaflet Patient Information leaflet German 06-04-2022
Public Assessment Report Public Assessment Report German 06-04-2022
Patient Information leaflet Patient Information leaflet Estonian 06-04-2022
Public Assessment Report Public Assessment Report Estonian 06-04-2022
Patient Information leaflet Patient Information leaflet Greek 06-04-2022
Public Assessment Report Public Assessment Report Greek 06-04-2022
Patient Information leaflet Patient Information leaflet English 06-04-2022
Public Assessment Report Public Assessment Report English 06-04-2022
Patient Information leaflet Patient Information leaflet French 06-04-2022
Public Assessment Report Public Assessment Report French 06-04-2022
Patient Information leaflet Patient Information leaflet Italian 06-04-2022
Public Assessment Report Public Assessment Report Italian 06-04-2022
Patient Information leaflet Patient Information leaflet Latvian 06-04-2022
Public Assessment Report Public Assessment Report Latvian 06-04-2022
Patient Information leaflet Patient Information leaflet Lithuanian 06-04-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 06-04-2022
Public Assessment Report Public Assessment Report Lithuanian 06-04-2022
Patient Information leaflet Patient Information leaflet Hungarian 06-04-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 06-04-2022
Public Assessment Report Public Assessment Report Hungarian 06-04-2022
Patient Information leaflet Patient Information leaflet Maltese 06-04-2022
Public Assessment Report Public Assessment Report Maltese 06-04-2022
Patient Information leaflet Patient Information leaflet Dutch 06-04-2022
Public Assessment Report Public Assessment Report Dutch 06-04-2022
Patient Information leaflet Patient Information leaflet Polish 06-04-2022
Public Assessment Report Public Assessment Report Polish 06-04-2022
Patient Information leaflet Patient Information leaflet Portuguese 06-04-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 06-04-2022
Public Assessment Report Public Assessment Report Portuguese 06-04-2022
Patient Information leaflet Patient Information leaflet Romanian 06-04-2022
Public Assessment Report Public Assessment Report Romanian 06-04-2022
Patient Information leaflet Patient Information leaflet Slovak 06-04-2022
Public Assessment Report Public Assessment Report Slovak 06-04-2022
Patient Information leaflet Patient Information leaflet Finnish 06-04-2022
Public Assessment Report Public Assessment Report Finnish 06-04-2022
Patient Information leaflet Patient Information leaflet Swedish 06-04-2022
Public Assessment Report Public Assessment Report Swedish 06-04-2022
Patient Information leaflet Patient Information leaflet Norwegian 06-04-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 06-04-2022
Patient Information leaflet Patient Information leaflet Icelandic 06-04-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 06-04-2022
Patient Information leaflet Patient Information leaflet Croatian 06-04-2022
Public Assessment Report Public Assessment Report Croatian 06-04-2022

View documents history